Clinical Program
Synergistic Drug Development

The SynDevRx clinical program is robustly designed to increase the likelihood of success. As we advance our best-in-class lead compound* through the regulatory process, we expect to continue contributing to the fundamental understanding of biology.

We are developing a pipeline of novel compounds that target MetAP2 in a formulation-dependent way. Our lead compound is currently undergoing pre-clinical studies, and is expected to be in human trials by 2009.

Development Team

Our clinical development team is comprised of highly experienced drug development professionals. We are efficiently moving our lead compound from pre-clinical testing to investigational new drug (IND) status and through human clinical trials.

The internal development group possesses expertise in the critical areas of process development, chemistry, manufacturing and controls (CMC), toxicology, pharmacology, and regulatory affairs. We believe our adaptability, creativity, persistence and fiscal discipline distinguish us from other biotech companies. We expect to create a valuable pipeline of anti-angiogenic compounds that have the potential to positively impact the lives of patients and doctors.

*This compound/technology is not yet available for clinical use in either the US or anywhere else in the world.